中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

5 records (took 0.01 seconds)

    Treatment of multiple sclerosis (MS) and other demyelinating conditions using lofepramine in combination with L-phenylalanine, tyrosine or tryptophan and possibly a vitamin B12 compound
    3.
    发明授权
    Treatment of multiple sclerosis (MS) and other demyelinating conditions using lofepramine in combination with L-phenylalanine, tyrosine or tryptophan and possibly a vitamin B12 compound 失效
    使用洛哌匹灵与L-苯丙氨酸，酪氨酸或色氨酸和可能的维生素B12化合物联合治疗多发性硬化（MS）和其他脱髓鞘病症

    公开(公告)号：US6096737A

    公开(公告)日：2000-08-01

    申请号：US817086

    申请日：1997-06-27

    Applicant: Cari Loder

    Inventor： Cari Loder

    IPC: A61K45/06 ,  A61K31/00 ,  A61K31/195 ,  A61K31/198 ,  A61K31/55 ,  A61K31/555 ,  A61K31/66 ,  A61K31/70 ,  A61P25/00 ,  A61P37/00 ,  A61K31/135

    CPC classification number: A61K31/688 ,  A61K31/00 ,  A61K31/55 ,  A61K31/714

    Abstract: The use of a combination of a tricyclic or tetracyclic antidepressant, a serotonin reuptake inhibitor, or a monoamine oxidase inhibitor with a neurotransmitter-inducing or precursor compound is proposed in the preparation of medication for the treatment or prevention of multiple sclerosis or other demyelinating conditions. For use in treatment to ameliorate the effects of a demyelinating condition, a daily regime is proposed of from 10 to 220 mg lofepramine and from 100 mg to 5 g of L-phenylalanine, optionally supplemented with injections of vitamin B.sub.12.

    Abstract translation: PCT No.PCT / GB95 / 02361 Sec。 371日期：1997年6月27日 102（e）日期1997年6月27日PCT提交1995年10月5日PCT公布。 公开号WO96 / 11009 日期1996年4月18日提出了用于治疗或预防多发性硬化的药物的制备中使用三环或四环抗抑郁药，5-羟色胺再摄取抑制剂或单胺氧化酶抑制剂与神经递质诱导或前体化合物的组合 或其他脱髓鞘状况。 为了改善脱髓鞘病症的疗效，提出了10至220mg洛哌匹明和100mg至5g L-苯丙氨酸的日常制度，任选地补充了维生素B12的注射。

    Treatment of fatigue, head injury and stroke
    4.
    发明授权
    Treatment of fatigue, head injury and stroke 失效
    疲劳，头部损伤和中风的治疗

    公开(公告)号：US06441038B1

    公开(公告)日：2002-08-27

    申请号：US09686629

    申请日：2000-10-12

    Applicant: Cari Loder ,  David F. Horrobin

    Inventor： Cari Loder ,  David F. Horrobin

    IPC: A61K31195

    CPC classification number: A61K31/55 ,  A61K45/06 ,  A61K2300/00

    Abstract: A method of treatment of disorders of neurological origin and drug formulations for use in the method are disclosed. These conditions comprise fatigue and associated syndromes of pain, weakness and depressed mood which are associated with chronic fatigue syndrome, brain injury and stroke, stress, fibromyalgia, and irritable bowel syndrome. The treatment comprises administering to a patient in need thereof a selective inhibitor of noradrenaline reuptake combined with either phenylalanine or tyrosine in the same dosage form or the same pack.# The noradrenergic drug may be selected from lofepramine, desipramine or reboxetine. The selective inhibitor may be a combined inhibitor of both noradrenaline and serotonin reuptake such as venlafaxine, duloxetine or milnacipran, or an inhibitor of both noradrenaline and dopamine reuptake such as bupropion.

    Abstract translation: 公开了一种治疗神经源性疾病的方法和用于该方法的药物制剂。 这些病症包括与慢性疲劳综合征，脑损伤和中风，压力，纤维肌痛和肠易激综合征相关的疲劳和相关的疼痛，虚弱和抑郁情绪综合征。 该治疗包括向有需要的患者施用去甲肾上腺素再摄取的选择性抑制剂与相同剂型或相同包装中的苯丙氨酸或酪氨酸组合。＃去甲肾上腺素能药可以选自洛哌匹灵，地昔帕明或瑞波西汀。 选择性抑制剂可以是去甲肾上腺素和5-羟色胺再摄取的组合抑制剂，如文拉法辛，度洛西汀或米那普仑，或去甲肾上腺素和多巴胺再摄入如安非他酮的抑制剂。

Patent Agency Ranking